NCT06219499 2024-04-03
Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841
OncoC4, Inc.
Phase 1 Withdrawn
Clinical Trials
4 trialsNCT05381935 2023-01-31
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma, Ltd.
Phase 1 Withdrawn
NCT04797468 2023-01-17
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
Shanghai Henlius Biotech
Phase 1 Withdrawn
NCT04878484 2022-09-02
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
Athenex, Inc.
Phase 1 Withdrawn